{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Cancers&page=3",
    "query": {
      "condition": "Hematological Cancers",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 326,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Cancers&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Cancers&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T03:46:14.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00433745",
      "title": "Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia (AML)",
        "Chronic Myeloid Leukemia (CML)"
      ],
      "interventions": [
        {
          "name": "WT1 Peptide Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 4,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2014-07-08",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433745"
    },
    {
      "nct_id": "NCT01627275",
      "title": "Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Naive T Cell Depleted Donor Lymphocyte Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mitchell Horwitz, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2012-06",
      "completion_date": "2017-08-03",
      "has_results": false,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627275"
    },
    {
      "nct_id": "NCT03711604",
      "title": "Compassionate Use Study of Tenalisib (RP6530)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Tenalisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhizen Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-11-28",
      "completion_date": "2023-03-25",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Denver, Colorado • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03711604"
    },
    {
      "nct_id": "NCT01931644",
      "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Diagnosed Health Conditions",
        "ADD/ADHD",
        "Alopecia Areata",
        "Ankylosing Spondylitis",
        "Asthma",
        "Atopic Dermatitis Eczema",
        "Beta Thalassemia",
        "Bipolar Disorder",
        "Breast Cancer",
        "Celiac Disease",
        "Cervical Cancer",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Chronic Kidney Diseases",
        "Chronic Obstructive Pulmonary Disease",
        "Colon Cancer",
        "Colorectal Cancer",
        "Crohn's Disease",
        "Cystic Fibrosis",
        "Depression",
        "Diabetes Mellitus",
        "Duchenne Muscular Dystrophy",
        "Endometriosis",
        "Epilepsy",
        "Facioscapulohumeral Muscular Dystrophy",
        "G6PD Deficiency",
        "General Anxiety Disorder",
        "Hepatitis B",
        "Hereditary Hemorrhagic Telangiectasia",
        "HIV/AIDS",
        "Human Papilloma Virus",
        "Huntington's Disease",
        "Idiopathic Thrombocytopenic Purpura",
        "Insomnia",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lupus Nephritis",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Multiple Sclerosis",
        "Myositis",
        "Myotonic Dystrophy",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Parkinson's Disease",
        "Polycystic Kidney Diseases",
        "Prostate Cancer",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Rosacea",
        "Scleroderma",
        "Sickle Cell Anemia",
        "Sickle Cell Trait",
        "Sjogren's Syndrome",
        "Skin Cancer",
        "Spinal Muscular Atrophy",
        "Systemic Lupus Erythematosus",
        "Thrombotic Thrombocytopenic Purpura",
        "Trisomy 21",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanguine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17667,
      "start_date": "2013-07",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931644"
    },
    {
      "nct_id": "NCT06801002",
      "title": "Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "JBZ-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jabez Bioscience, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2025-03-17",
      "completion_date": "2028-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • West Valley City, Utah",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06801002"
    },
    {
      "nct_id": "NCT01527045",
      "title": "Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aggressive Non-Hodgkin Lymphoma",
        "Blasts Under 5 Percent of Bone Marrow Nucleated Cells",
        "Chronic Lymphocytic Leukemia",
        "Loss of Chromosome 17p",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Non-Hodgkin Lymphoma",
        "Prolymphocytic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Aggressive Adult Non-Hodgkin Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Atorvastatin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 47,
      "start_date": "2012-09-25",
      "completion_date": "2019-04",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527045"
    },
    {
      "nct_id": "NCT06799195",
      "title": "Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Graft-versus-Host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Attenuated-dose Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "High-dose Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2025-06-23",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06799195"
    },
    {
      "nct_id": "NCT02071888",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma (NHL)",
        "Multiple Myeloma",
        "Waldenstrom's Macroglobulinemia (WM)",
        "Other B-cell NHL Subtypes, Including WM",
        "T-cell NHL"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "CB-839 and low dose dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "CB-839, pomalidomide, and low dose dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-02",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071888"
    },
    {
      "nct_id": "NCT00446342",
      "title": "Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-lymphoid Malignancies",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "SNS-032 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunesis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2007-02",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Stanford, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446342"
    },
    {
      "nct_id": "NCT04937166",
      "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "DSP107",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kahr Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-01-13",
      "completion_date": "2025-10-24",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-07T03:46:14.173Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04937166"
    }
  ]
}